Nov
08
Direct and Background Efficacy: A Framework for Why Pain Formulas Need Both
0 Comments
Painkillers quiet the alarm. They do nothing about whatever keeps setting it off. A 2022 framework splits analgesia into those two jobs, names which compounds do which, and maps the split onto a formula structure written down centuries ago.
The short version
Think of chronic pain as a fire alarm that will not stop. There are two ways to deal with it. You can cut the wire to the bell, or you can find out what keeps triggering the sensor.
Conventional painkillers cut the wire. Opioids, anticonvulsants and local anaesthetics all suppress the signal, which works and is sometimes exactly what is needed. The trouble is that the conditions generating the signal are untouched, so the dose creeps up over time.
What keeps the sensor firing in long-term pain is reasonably well understood: inflammation around the nerves, oxidative stress, activation of the nervous system’s support cells, and a lost balance between the accelerator and brake signals in the spinal cord.
A 2022 review proposed naming these two jobs and treating them as separate axes. Direct efficacy is cutting the wire. Background efficacy is addressing what sets it off. The authors call the two-axis picture the drug cloud, or dCloud, and note that combination treatment benefits 30 to 50 percent of chronic pain patients.
Then the part worth the price of admission. They map the two axes onto Jun, Chen, Zuo and Shi, the four roles classical Chinese formulas assign to their ingredients. The structure already existed.
What to do with that: use the two axes to audit any pain formula, your own or a product you are considering. Ask which ingredient suppresses the signal and which addresses inflammation, glial activation or oxidative stress. A formula that is entirely direct will need escalating doses; one that is entirely background will feel like it does nothing at first. The useful ones cover both, and you can tell which is which from an ingredient list once you know the question.
The two axes
Direct efficacy covers inhibiting ion channels and activating GABA or opioid receptors, suppressing the pain signal itself.
Background efficacy covers reducing neuronal inflammation and oxidative stress, inhibiting glial cell activation, and restoring the balance between excitatory and inhibitory neurotransmission. The authors describe this axis as addressing the root causes of chronic pain (Jiang et al., 2022).
Glial activation deserves a note, since it is the part most people have never heard of. Glia are the support cells of the nervous system, long assumed to be passive scaffolding. In chronic pain they are not passive. Activated glia release inflammatory signals that make neighbouring neurons more excitable, so the nervous system amplifies its own pain signalling. That is a plausible mechanical account of how acute pain becomes chronic, and nothing in a conventional painkiller addresses it.
The structure was already there
Classical Chinese formulas assign every ingredient one of four roles. The review maps them directly:
- Jun, the sovereign, acts directly on the major symptom
- Chen, the minister, generates the major background effects
- Zuo, the assistant, has supportive and moderating functions
- Shi, the envoy, facilitates delivery of the drugs to the target tissue
Jun is direct efficacy. Chen is background efficacy. Zuo manages side effects. Shi handles pharmacokinetics, which is the part that tends to astonish people, because a system with no concept of hepatic metabolism still reserved a functional slot for getting the active where it needs to go.
Our article on multi-target formulations covers a measured example of the envoy role, where a whole formula delivered ten times more of its own active compound into circulation than the isolated compound managed alone.
The compounds
The review works through the best studied analgesic alkaloids from Chinese medicine, among them tetrahydropalmatine, aloperine, oxysophocarpine, matrine, sinomenine, ligustrazine, evodiamine, brucine, tetrandrine and lappaconitine.
Two names on that list connect to work covered elsewhere on this site.
Sinomenine appears here as an analgesic alkaloid and separately in our article on autophagy, where it inhibits PI3K/AKT/mTOR and restores autophagy in a mouse model of Parkinson’s disease. One compound, two literatures, which is what a background-efficacy agent looks like when somebody studies it for something else.
Matrine and oxysophocarpine come from the genus Sophora, the same genus as Ku Shen, whose alkaloid oxymatrine is covered in our article on that plant. A single genus supplying several related alkaloids across pain and aging research is a reasonable place to look for more.
Why this belongs in a longevity file
Chronic pain looks like a separate subject from aging until the mechanisms are listed side by side. Neuronal inflammation, oxidative stress and glial activation are the same processes that appear under inflammaging, and they rise with age for the same reasons.
The dCloud framework is also the clearest statement of the general case anyone has published. Replace pain with any multifactorial condition and the structure holds: something for the presenting problem, something for the conditions sustaining it, something to moderate side effects, something to handle delivery. That is a formulation template, derived from pain research, usable anywhere.
Limitations
The 30 to 50 percent figure describes drug combinations in chronic pain generally rather than any specific botanical formula, and the alkaloids discussed here are supported largely by preclinical work, so the framework is better treated as a way of organising evidence than as a claim about any particular product.
Citations
[1] Jiang W, Tang M, Yang L, et al. Analgesic alkaloids derived from traditional Chinese medicine in pain management. Front Pharmacol. 2022;13:851508. PMID 35620295
[2] Bao et al. Sinomenine exerts a neuroprotective effect on PD mouse model through inhibiting PI3K/AKT/mTOR pathway to enhance autophagy. Int J Neurosci. 2024. PMID 35815397
[3] Liu JM, Chen JM, Lin MJ, et al. Screening and verification of CYP3A4 inhibitors from Bushen-Yizhi formula to enhance the bioavailability of osthole. J Ethnopharmacol. 2022;282:114643. PMID 34534597
These statements have not been evaluated by the Food and Drug Administration. Nothing here is intended to diagnose, treat, cure or prevent any disease, and nothing here is medical advice. Chronic pain should be managed with a clinician.
Categories:
MDS Research Articles
